Genetron Holdings Past Earnings Performance
Past criteria checks 0/6
Genetron Holdings's earnings have been declining at an average annual rate of -62.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 22.3% per year.
Key information
-62.9%
Earnings growth rate
-61.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 22.3% |
| Return on equity | -147.8% |
| Net Margin | -124.2% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Genetron Holdings GAAP EPS of -$0.08, revenue of $20.56M
Oct 12China's Genetron gets acquisition offer from co-founder/CEO
Aug 22Are Investors Undervaluing Genetron Holdings Limited (NASDAQ:GTH) By 27%?
Dec 07
Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 17Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22
Mar 27Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?
Feb 25Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China
Jan 06Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China
Nov 27Genetron (GTH) Investor Presentation - Slideshow
Nov 18Genetron Holdings reports Q3 results
Nov 09Revenue & Expenses BreakdownBeta
How Genetron Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 651 | -808 | 690 | 290 |
| 30 Sep 22 | 596 | -772 | 695 | 301 |
| 30 Jun 22 | 547 | -701 | 656 | 289 |
| 31 Mar 22 | 550 | -558 | 644 | 284 |
| 31 Dec 21 | 532 | -496 | 607 | 254 |
| 30 Sep 21 | 519 | -407 | 521 | 221 |
| 30 Jun 21 | 478 | -326 | 457 | 198 |
| 31 Mar 21 | 440 | -3,066 | 417 | 171 |
| 31 Dec 20 | 424 | -3,069 | 388 | 149 |
| 30 Sep 20 | 393 | -3,131 | 355 | 128 |
| 30 Jun 20 | 363 | -3,357 | 361 | 111 |
| 31 Mar 20 | 334 | -660 | 365 | 100 |
| 31 Dec 19 | 323 | -676 | 373 | 92 |
| 30 Sep 19 | 294 | -666 | 366 | 80 |
| 31 Dec 18 | 225 | -465 | 271 | 71 |
| 31 Dec 17 | 101 | -421 | 140 | 46 |
Quality Earnings: GTH is currently unprofitable.
Growing Profit Margin: GTH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GTH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: GTH has a negative Return on Equity (-147.83%), as it is currently unprofitable.